Manufacturing and quality control data: all parameters have been inspected and approved during the manufacturing process.All parameters have been assessed as meeting specifications.Investigation: visual inspection: scratches on the outer housing of the valves were observed through the visual inspection.No significant deformations or damages were detected.Permeability test: a permeability test has shown that both valves are permeable adjustment test: the progav 2.0 valve was tested and is adjustable to all specified pressures.Braking force and brake function test: the brake functionality test has shown that the brake function is fully operational and the braking force is within the given tolerances.Computer controlled test: to test the opening pressure, we use a miethke computer controlled testing apparatus, which simulates a cerebrospinal fluid flow.The tests have shown that both valves are operating within acceptable tolerances.Results: we have dismantled the valve.Inside both valves we have found significant build up of substances (likely protein).Based on our investigation, we are unable to substantiate the claim of occlusion or of underdrainage.The valves operate within the specified tolerances.However it is possible that the deposits observed inside the valves could have temporarily caused the malfunction if the past.As described in our literature, the problem encountered is one of the known inevitable risks of hc-therapy by shunt implants.
|